Document is current
Any future updates will be listed below
-
Authors
Sanborn, Rachel E
Furqan, Muhammad
Laux, Doug
Sharma, Manish
Olson, Daniel
Berz, David
Hauke, Ralph J
Massarelli, Erminia
Steuer, Conor
Davis, Elizabeth
Iams, Wade T
Thompson, Jonathan
Hamm, John
Andrianov, Vasily
O’Neill, Brianne
Durana, Yaiza Diaz De
Tolcher, Anthony W
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04198766 at ClinicalTrials.govnct04198766 at ClinicalTrials.govDocuments that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
Documents that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
- License Information
